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Abstract—Extensive changes in neural tissue structure and
function accompanying Alzheimer’s disease (AD) suggest
that intrinsic signal optical imaging can provide new contrast
mechanisms and insight for assessing AD appearance and
progression. In this work, we report the development of a
wide-ﬁeld spatial frequency domain imaging (SFDI) method
for non-contact, quantitative in vivo optical imaging of brain
tissue composition and function in a triple transgenic mouse
AD model (3xTg). SFDI was used to generate optical
absorption and scattering maps at up to 17 wavelengths from
650 to 970 nm in 20-month-old 3xTg mice (n = 4) and age-
matched controls (n = 6). Wavelength-dependent optical
properties were used to form images of tissue hemoglobin
(oxy-, deoxy-, and total), oxygen saturation, and water.
Signiﬁcant baseline contrast was observed with 13–26%
higher average scattering values and elevated water content
(52 ± 2% vs. 31 ± 1%); reduced total tissue hemoglobin
content (127 ± 9 lM vs. 174 ± 6 lM); and lower tissue
oxygen saturation (57 ± 2% vs. 69 ± 3%) in AD vs. control
mice. Oxygen inhalation challenges (100% oxygen) resulted
in increased levels of tissue oxy-hemoglobin (ctO2Hb) and
commensurate reductions in deoxy-hemoglobin (ctHHb),
with ~60–70% slower response times and ~7 lM vs. ~14 lM
overall changes for 3xTg vs. controls, respectively. Our
results show that SFDI is capable of revealing quantitative
functional contrast in an AD model and may be a useful
method for studying dynamic alterations in AD neural tissue
composition and physiology.
Keywords—Structured light, Vascular reactivity, Hyperoxia,
In vivo spectroscopy, Microvascular perfusion, Diffuse
optical imaging, Scattering, Absorption, Tissue optical
properties.
INTRODUCTION
More than 35 million people world-wide have
Alzheimer’s disease (AD), a neurodegenerative disease
characterized by amyloid-beta (Ab) plaque and neu-
roﬁbrillary tau tangle accumulation accompanying
neuron death.
31 The cause of sporadic AD, accounting
for 85% of cases, is unknown, but increasing evidence is
revealing diverse co-factors may all lead to the patho-
logical neurodegeneration seen in AD.
26 Vascular dis-
eases such as atherosclerosis, diabetes mellitus, and
stroke are major risk factors. Cerebral stroke alone
increases AD prevalence in elderly patients twofold.
Hypoxia, which can be caused by hypoperfusion from
atherosclerosis or sleep apnea, is shown in vitro,i n
ex vivo human brain and in vivo animal models to
increase Ab production and inhibit degradation and
clearance.
44 These studies give evidence that vascular
dysfunction and Ab pathology are closely intertwined.
In the last 10 years, imaging research using
laser speckle,
33 transcranial doppler,
34,36,40 fMRI,
18,43
PET,
37 and SPECT
30 techniques have all described
impaired vascular reactivity in AD in response to
vasodilation challenges. The implication is that AD
patients have a diminished ability to vasodilate in
response to hypoxia, leading to hypoxic stress in neu-
rons and subsequent Ab production. Since there is
evidence that Ab oligomers are the damaging species to
vascular function,
11,16,27 and it is hypothesized that
decreased vascular reactivity induces further amyloid
pathology, a vicious cycle might ensue.
Brain imaging oﬀers a unique approach to studying
and managing AD without invasive biopsies. However,
imaging with resource-limited fMRI, PET, and SPECT
for resolving regions of relatively impaired brain
metabolism and radiolabeling AD pathology with
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1349expensive dyes (e.g., Pittsburgh compound B) is not
feasible for most animal researchers or human patients.
Because all patients have unique, dynamic responses,
the ideal imaging device would allow frequent,low cost,
rapid measurements of brain function without risk.
Tissue optical spectroscopy can provide those
features. Non-ionizing radiation is used to measure
physiologic function, such as the concentration of
oxy- and deoxy-hemoglobin (ctO2Hb and ctHHb)
(indicators of perfusion and metabolism), tissue oxygen
saturation, and lipid and water content at an arbitrary
number of time points.
6,39 In research, intrinsic signal
optical imaging, which focuses on hemoglobin oxygen-
ation signals, has been widely used to study hemody-
namics in the brain during stroke and seizures.
7,13,22
Other tools including laser speckle
4 and transcranial
doppler
23 imaging are used in research and the clinic to
measure changes in blood ﬂow.
Spatial frequency domain imaging (SFDI) supple-
ments the imaging repertoire as a wide ﬁeld, non-con-
tact, intrinsic signal technique capable of measuring
tissue absorption and scattering properties on a pixel-
by-pixel basis. This is done by imaging the frequency-
dependent reﬂectance of a spatially modulated light
source projected onto tissue. Tissue optical properties
(i.e., absorption, la, and reduced scattering, l0
s; para-
meters) are calculated for each source wavelength by
ﬁtting the demodulated SFDI signals to a light trans-
port model.
9 Images of intrinsic chromophore con-
centration including ctO2Hb, ctHHb, water, and lipid
are obtained by analyzing the wavelength dependence
of light absorption.
SFDI maps of tissue scattering parameters provide
unique structural contrast that complements func-
tional information derived from light absorption.
Factors in brain tissue scattering such as cell or orga-
nelle swelling from edema
15 and vasodilation from
cortical activation
38 have been elucidated in vivo.I n
addition, tissue scattering coefﬁcients have been shown
to be elevated in ex vivo human AD brain tissue
17 and
are highly sensitive to cell death in vitro
28 and ex vivo.
14
SFDI has been well-characterized for tissue spectros-
copy
1,3,8 and it has tomography, depth-sectioning, and
ﬂuorescence measurement capabilities.
20,25,42 In this
work, we demonstrate that SFDI measurements of
absorption and scattering signatures in a transgenic
mouse model can be used to differentiate AD pathol-
ogy from normal aging.
MATERIALS AND METHODS
Animal Model
Alzheimer’s triple transgenic (3xTg) mice expressing
human APP/PS1/tau genes on a C57/BL6-129svj
background express both hallmark lesions of AD, Ab
plaques, and tau tangles. Both protein aggregates are
toxic to neurons and microvasculature, making the
3xTg mouse an ideal model for studying neurovascular
disease. 3xTg male mice were studied at 20 months of
age (n = 4) to coincide with the appearance of
advanced plaque and tangle pathology. Age-matched
C57/BL6-129svj mice (n = 6) were used to control
for changes due to normal aging. All procedures
were performed in accordance with the regulations of
the Institutional Animal Care and Use Committee
(IACUC) of the University of California, Irvine
(protocol no. 2010-2934).
Imaging windows were created under gas mask
isoﬂurane anesthesia (2% maintenance in 21% oxygen
balanced by nitrogen) by removing the skin from
bregma anteriorly to lambda posteriorly and bilater-
ally to the temporalis muscle attachments. The mouse
skull, 200–700 lm thick, was left intact to reduce
trauma artifact from removing or thinning it. This
approach has been used widely in intrinsic signal
imaging of mouse brain.
13 During the initial surgery
and for the imaging session, the mouse was heated by a
thermostatically controlled heating pad (Gaymar).
Immediately after surgery, the mouse’s head was
secured by adjustable machined ear bars to prevent
motion and a thin layer of heavy mineral oil was
applied onto the cranium to reduce skull drying.
2,21
Excess gases were scavenged via a Bickford adsorber
unit and gas ﬂow was maintained at 2.4 L/min.
Steady-State Measurement and Hyperoxia Challenge
An initial 17-wavelength (650–970 nm, every 20 nm)
baseline measurement was acquired continuously for
2 min with the mouse breathing 21% O2 (normoxia).
Immediately following the 17-wavelength scan, base-
line and dynamic measurements were recorded during
an 8 min, 100% oxygen inhalation challenge using only
670 and 850 nm light to achieve a time resolution of
about 15 s/measurement while still containing hemo-
globin chromophore information. Normoxia was used
to measure the baseline optical properties again for
3 min followed by 100% O2 (hyperoxia) as an experi-
mental perturbation for 5 min. Doing a challenge
allowed us to test the brain’s reactivity relative to each
mouse’s baseline values, which reduced the effects of
variation in a population of mice. In addition to base-
line measurements, it could potentially increase sensi-
tivity to neurovascular defects found in AD mice.
SFDI Instrument and Analysis
A schematic of the experimental arrangement is
illustrated in Fig. 1. A complete description of SFDI
LIN et al. 1350instrumentation and data analysis has been previously
presented.
8,9 Brieﬂy, broadband near-infrared (NIR)
light from a 250 W quartz-tungsten halogen light
source (Newport Corporation, Irvine, CA) was shaped
into sinusoidal projection patterns by a computer-
controlled DLP Developer’s Kit (Texas Instruments,
Dallas, TX), consisting of a 1024 9 768 pixel digital
micromirror device, and focused by a set of lenses onto
the mouse’s cranium at a working distance of 750 mm.
For both the low AC frequency (f = 0m m
21)a n d
high AC frequency (f = 0.125 mm
21), three adjacent
light intensity patterns phase-shifted 120  were pro-
jected and images were captured across a speciﬁed
range of wavelengths by a Nuance Multispectral
Imaging System (CRI, Inc., Woburn, MA) with a
liquid–crystal tunable ﬁlter.
The tissue-modulated reﬂected images at each phase
(i.e., I1, I2, I3), consisting of both an AC and DC
(Eq. 1) component, were then demodulated to create a
composite reﬂected image for each AC frequency
(MAC) with the DC component subtracted out (Eq. 2).
In ¼ InDC þ InAC ð1Þ
MAC ¼
ﬃﬃﬃ
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p
3
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The ﬁnal diﬀuse reﬂectance image for each fre-
quency was calculated by calibrating to a silicone
phantom of known optical properties, which corrects
for any system response due to spatial variation of the
illumination light and lens aberrations. The mean
photon path length in tissue depends on the projected
spatial frequency and, hence, recorded light becomes a
nonlinear function of this parameter, absorption (la),
and reduced scattering ðl0
sÞ coefﬁcients. A known
Monte Carlo forward model
8 was then used to create a
look-up table for ﬁtting these optical properties on a
pixel-by-pixel basis.
Quantitative concentration values of ctO2Hb,
ctHHb, total Hb (ctO2Hb + ctHHb), tissue oxygen
saturation (100 * ctO2Hb/Total Hb), and percent
water were calculated from the absorption spectrum
according to the Beer–Lambert law (la = 2.3eC, where
e is the known molar extinction coefﬁcient for each
chromophore and C is the molar concentration). In
addition, the wavelength-dependent scattering was ﬁt
to a model based on the Mie theory approximation,
l0
s ¼ Ak
 b; commonly used in tissue optics, where k is
the optical wavelength and ‘‘A’’ and ‘‘b’’ are free
variables determined by a least squares ﬁt.
41
For each image, the region of interest (ROI) was
anatomically standardized between the suture junc-
tions bregma and lambda and bilaterally to the tem-
poralis muscle attachments (Fig. 1). The average and
standard deviation (SD) of pixel intensities in the ROI
(~5000 pixels) for each mouse were calculated. The
within group SD (i.e., 3xTg vs. control) was calculated
using the average ROI pixel values for each mouse in
the group. All averages, standard error bars, and p
values shown were calculated from mean ROI and SD
values between animals in each group. A two-tailed
student’s t test analysis was used to determine signiﬁ-
cance between Alzheimer’s and control mice. All image
processing and analyses were done with MATLAB
software (Mathworks, Natick, MA).
RESULTS
Baseline Brain Optical Properties
Reduced scattering ðl0
sÞ and absorption (la) images
of the brain were determined at 21% O2 from 650
to 970 nm at 17 wavelengths spaced every 20 nm.
Scattering contrast revealed regional differences and
was higher in the ROI (red dotted box) in Alzheimer’s
mice (Fig. 2), while absorption showed a more
FIGURE 1. (Left) Schematic of SFDI imaging of mouse brain through the intact skull. Non-ionizing broadband light is projected
onto a spatial light modulator and light intensity patterns of different spatial frequencies are focused onto the mouse’s cranium.
The reﬂectance is captured by a CCD camera with a tunable liquid crystal ﬁlter to select for speciﬁc wavelengths of light. (Right)
Pixels in the region of interest (bregma to lambda and bilaterally to temporalis muscle attachments) are averaged for analyses.
Optical Imaging of Alzheimer’s Disease 1351homogeneous distribution and was generally lower in
Alzheimer’s brains. After averaging absorption values
in the ROI, the absorption spectrum was noticeably
lower in 3xTg mice, especially in the 750–950 nm range
(p<0.05). The spectra were ﬁt for hemoglobin and
water (Fig. 3)w i t hR
2 values of 0.98 and 0.95 for
control and 3xTg mice, respectively. Concentrations of
baseline chromophores are summarized in Table 1.
AD mice displayed elevated water content (52 ± 2%
vs. 31 ± 1%); reduced total tissue hemoglobin con-
tent (127 ± 9 lM vs. 174 ± 6 lM); and lower tissue
oxygen saturation vs. control mice (57 ± 2% vs.
FIGURE 2. Representative optical property maps of control and Alzheimer’s brains taken with SFDI in vivo at normal air (21% O2).
Pixel values in the ROI were averaged for each mouse and wavelength-dependent reduced scattering and absorption coefﬁcient
spectra were plotted for control and 3xTg mice (group average 6 group SE).
FIGURE 3. (a) Reduced scattering and (b) absorption spectra (group average 6 group SE shown) were ﬁt to the Mie scattering
power law ðl0
s ¼ Ak bÞ and for hemoglobin and water chromophores, respectively, with a least squares linear ﬁt and R
2 values were
found. *p<0.005, **p<0.001.
TABLE 1. Baseline normoxia values of chromophores
expressed as (mean 6 SE) in control (n 5 6) and 3xTg (n 5 4)
mouse groups.
Subject
ctO2Hb
(lM)
ctHHb
(lM)
Total Hb
(lM)
O2 sat
(%)
Water
(%)
Control
17wv 119 ± 65 5 ± 2 174 ± 66 9 ± 23 1 ± 2
3xTg
17wv 73 ± 6** 54 ± 4 127 ± 9** 57 ± 2** 52 ± 1**
Values determined from ﬁts to 17 wavelength SFDI absorption
spectra (650–970 nm).
**p<0.003.
LIN et al. 135269 ± 2%). Scattering was also signiﬁcantly higher
(13–26%) in 3xTg mice for all 17 wavelengths
(p<0.003), conﬁrming a previous ex vivo human
study of AD brain tissue.
17 The wavelength-dependent
scattering was ﬁt to the Mie theory approximation
with R
2 values of 0.97 and 0.99 for control and 3xTg
mice, respectively. Scattering pre-factor (A) and power
(b) values from the ﬁts showed signiﬁcant contrast at
baseline (Fig 3a).
With 670 and 850 nm acquisition data, chromo-
phore and scattering levels were determined by 3 min
baseline average values when the mice were breathing
21% O2 and after a new steady state was established
with 100% O2 gas mixtures. At normoxia (21% O2),
the baseline chromophore concentrations calculated
from the 670/850 nm data were close to the 17-wave-
length spectral ﬁts, differing an average of 5% in
chromophore values for controls. Notably, and just in
3xTg mice, average ctO2Hb level was much higher than
in the 17-wavelength ﬁts (100 lM vs. 73 lM), which
affected the Total Hb and O2 saturation calculations.
Water was not ﬁt for because 670 and 850 nm
absorption mainly has contributions from ctHHb and
ctO2Hb, respectively. Taking the more conservative
670/850 nm chromophore concentrations, however,
still showed total hemoglobin and ctO2Hb were
approximately 15 and 20% lower (p<0.05) in 3xTg
mice, respectively, compared to controls indicating
signiﬁcantly diminished baseline vascular perfusion in
the 3xTg mice. This conﬁrms a previous study showing
reduced vascular volume in 3xTg mice compared to
age-matched controls,
5 as evidenced by radioactive
inulin perfusion.
Dynamic Hyperoxia Challenge
To visualize the brain reactivity to hyperoxia, con-
tinuous measurements of chromophores and scattering
parameters were plotted in a time series as the inhaled
gas mixture was changed from 21% O2 to 100% O2
(Fig. 4). In this single challenge, a rise in ctO2Hb and
O2 saturation and a dip in ctHHb were seen. Neuro-
vascular reactivity to hyperoxia challenge was mea-
sured from the magnitude differences between baseline
FIGURE 4. Representative dynamic time courses in Alzheimer’s (thin lines) and control mice (thick lines) of (a) oxy-hemoglobin
(ctO2Hb, dotted lines) and deoxy-hemoglobin (ctHHb, continuous lines), (b) oxygen saturation (O2 sat), (c) total hemoglobin (Total
Hb), and (d) reduced scattering coefﬁcient at 670 nm (dotted lines) and 850 nm (continuous lines).
Optical Imaging of Alzheimer’s Disease 1353values and changes in ctO2Hb, ctHHb, % O2 satura-
tion, and scattering at 670 nm were signiﬁcantly
attenuated in 3xTg mice (Fig. 5). Furthermore, chro-
mophore dynamics were calculated as the slope at the
T50, or halfway point between the two baselines, and
found to be twofold to threefold slower in the 3xTg
mice (Table 2). In magnitude change and dynamics,
the total hemoglobin content in both 3xTg and control
mice stayed constant with hyperoxia challenge.
DISCUSSION
This pilot study is the ﬁrst to concurrently image
tissue hemoglobin content and scattering in vivo in an
AD model. Our results show signiﬁcantly impaired
vascular perfusion in the 3xTg’s which corroborates
previous 3xTg vascular volume results.
5 At 21% O2,
total Hb and ctO2Hb levels are about 27 and 39%
lower than control, respectively, potentially from
Ab-induced vasoconstriction
19 or impaired angiogen-
esis and decreased vessel density. The anesthesia agent,
isoﬂurane, is a potent vasodilator
12 and baseline
differences in absorption and scattering could also
be explained by an attenuated vasodilation response
in the 3xTg mice compared to controls. In addition,
a 20% differential increase in brain water content in
3xTg mice over controls was observed, potentially
indicating edema and decreased cellularity (a signiﬁ-
cant source of water signals) associated with AD. Our
observations of elevated water and reduced hemoglo-
bin content are generally consistent with AD progres-
sion which produces neural cell atrophy and
concomitant reduction in vascular supply.
31 Histologic
vascular formation analyses and tissue biochemical
assays, as well as hypercapnia-induced vasodilation
studies, are planned for future experiments to further
characterize the 3xTg AD mouse model.
The in vivo ﬁndings of increased NIR scattering in
3xTg mice compared to controls strengthens a previ-
ous ex vivo human study that showed increased NIR
reduced scattering coefﬁcients in post-mortem ﬂash-
frozen AD brain samples.
17 The wavelength-depen-
dent scattering spectra revealed a twofold decrease in
the scatter pre-factor (A) value and slight (~11%)
decrease in scatter power (b) value. The scatter pre-
factor is positively correlated with scatterer density
and the scatter power is negatively correlated with
scatterer size,
35 indicating 3xTg mice on average may
have decreased scatterer density and increased scat-
terer size compared to controls. Overall, elevated
scattering values are suggestive of AD neural tissue
with higher refractive index particles/discontinuities
compared to controls. Although the precise structural
origin of the scattering signal is not known, it could
be a result of contributions from cellular dystrophies,
microgliosis, demyelination, and/or Ab-induced
vasoconstriction and ﬁbrosis found in the 3xTg mice
previously.
10,19,24,29 These observations are generally
consistent with the absorption-spectra impressions of
diminished vascular content, cellular atrophy, and
edema.
FIGURE 5. Hemoglobin and scattering at 670/850 nm magnitude changes between three min baselines during 21% O2 and 100%
O2 were reduced in 3xTg mice compared to controls (group average 6 group SE).
TABLE 2. Rates of chromophore change, expressed as
(mean 6 SE) in control (n 5 6) and 3xTg (n 5 4), measured
during hyperoxic challenge.
Subject
ctO2Hb
(lM/s)
ctHHb
(lM/s)
Total Hb
(lM/s)
O2 sat
(%/s)
Control 0.74 ± 0.05 0.74 ± 0.06 0.04 ± 0.01 0.4 ± 0.02
3xTg 0.32 ± 0.03** 0.24 ± 0.06** 0.02 ± 0.01 0.2 ± 0.02**
**p<0.001.
LIN et al. 1354The absolute scattering measurement accuracy is
aﬀected by contributions from the mineral oil and
skull, and the imprecision of the light transport model.
We used a homogeneous Monte Carlo model because
our preliminary experiments on test animals indicated
that mineral oil (vs. dry skull) and mineral oil skull
(vs. no skull) account for relatively small reductions
in scattering (~7 and ~10%, respectively, data not
shown), while the physiological beneﬁt of maintaining
intact skull in terms of reducing trauma, swelling, and
motion artifact is well-established. In addition, the
thinness of the mouse’s skull (~500 lm) and the small
size of the brain (<1 cm) preclude us from rigorously
applying a two-layer SFDI analysis as we previously
performed in tissue phantom systems, where the upper
layer thickness signiﬁcantly exceeded the transport
scattering length.
42 Thus, while relative comparisons
between AD and control mice are valid for a given
anesthesia agent/dose, characterization of absolute
values requires further technology and animal model
development.
Supplementing the observed static absorption and
scattering contrast our results show for the ﬁrst time
that a hyperoxia challenge can be used to reveal
dynamic contrast in AD mice. Hyperoxia is known
to induce microvascular vasoconstriction, possibly
through prostaglandin synthesis inhibition or reactive
oxygen species formation.
32 However, SFDI was not
sensitive to these microvascular changes as seen by lack
of total hemoglobin changes. Both AD and control
mice showed an expected increase in ctO2Hb and
symmetric drop in ctHHb due to enhanced delivery of
HbO2. However, the same challenge produced twofold
less increase in ctO2Hb in 3xTg mice. This offers an
additional sensitive metric in which a lower vascular
volume would limit increase in blood oxygenation, and
it conﬁrms the baseline results that vascular perfusion
is impaired in the AD mice.
Surprisingly, a small increase in 670 nm scattering
was observed in controls vs. 3xTg mice in response to
the hyperoxia challenge, while 850 nm scattering
changed little. While tissue scattering could change in
response to alterations in intra- vs. extracellular water
content,
15 and this balance may be perturbed by gas
inhalation challenges, the small changes in scattering
values may also be an artifact of absorption crosstalk
since incomplete separation of la from l0
s is particu-
larly problematic under conditions of high absorption
(i.e., 670 nm).
8
In summary, 3xTg baseline ctO2Hb and total Hb
were 61 and 73% of normal, respectively, and we show
averages of 13–26% higher scattering contrast values
(650–970 nm) in resting AD brains in vivo for the
ﬁrst time. Both the magnitude and rate of change
of chromophore signals to hyperoxia challenge are
substantially reduced in 20-month-old 3xTg subjects
compared to age-matched controls, suggesting neuro-
vascular reactivity impairment in AD mice. These
preliminary results are limited because of the small
sample size and the need to include additional age
groups to deﬁnitively characterize the effects of normal
aging. Nevertheless, we have demonstrated that SFDI
is sensitive to intrinsic tissue optical properties that can
be obtained in vivo to distinguish AD-induced brain
pathology from age-matched controls. The structural
and functional origin-of-contrast is consistent with
previously reported studies, and SFDI may be useful in
quantifying spatial and temporal features of AD
appearance, progression, and response to therapy. In
addition, because optical contrast obtained from SFDI
in animal models can be correlated to diffuse optical
tomography (DOT) and f-MRI brain imaging studies
in humans, this approach provides a platform to
inform further clinical translational studies in humans.
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